Can a new lens give sharper sight at all distances?

NCT ID NCT06111222

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial investigates how well a new multifocal intraocular lens, the AT ELANA, improves vision in people having cataract or refractive lens exchange surgery. About 69 participants will receive the lens in both eyes and be followed for 12 months to measure visual sharpness and satisfaction. The goal is to see if the lens provides clear vision at near, intermediate, and far distances, potentially reducing dependence on glasses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a multifocal intraocular lens called AT ELANA
What this could lead to
If successful, this lens could provide clearer vision at multiple distances, reducing the need for glasses after cataract or lens exchange surgery.
What could go wrong
This is a small, non-randomized study with no control group, so results may not apply broadly. Some patients may experience glare or halos with multifocal lenses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

69 people

The number who actually took part.

Started

Oct 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older; * Patients scheduled for bilateral AT ELANA 841P phacoemulsification cataract extraction or Femtosecond-Laser-Assisted-Cataract-Surgery (cataract grades of 1, 2, 3 on the LOCSIII scale) and IOL implantation (Cataract or PRELEX) with a maximum of 28 days between both implantations; Calculated IOL power within the limited IOL Diopter range of +15.0D to +27.0D * No visual acuity limiting pathologies other than cataract; * Corneal Astigmatism of \<1.0 D; * Availability, willingness, and sufficient cognitive awareness to comply with examination procedures; * Written informed consent for participation in the study and data protection. Exclusion Criteria: * Corneal Astigmatism of ≥1.0 D; * Difficulty for cooperation (distance from their home, general health conditions); * History of acute or chronic disease, pathology, illness, or ocular trauma that would, in the surgeon's opinion, confound results (e.g., corneal pathology, OHT, glaucoma suspect, glaucoma, macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, amblyopia, etc.); * Visual field loss which has an impact on visual acuity; * Use of systemic or ocular medication that might affect vision; * Patients with amblyopia, strabismus, forme fruste keratoconus or keratoconus; * Pupil abnormalities (non-reactive, tonic pupils, abnormal myosis or mydriasis, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions); * Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g., pseudoexfoliation syndrome); * Cataract grades of 4, 5 or 6 on the LOCSIII scale ; * Surgeries with incision size of ≥2.75mm ; * Immediate Sequential Bilateral Cataract Surgery ; * Concurrent participation in another device investigation; * Usage of contact lenses during participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ofatlivist Alicante

    Alicante, 03001, Spain

  • PVK Precise Vision GmbH

    Rheine, 48429, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.